Literature DB >> 2824211

Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy.

P E Postmus1, H H Berendsen, N van Zandwijk, T A Splinter, J T Burghouts, W Bakker.   

Abstract

In 37 patients with small cell lung cancer treatment with five cycles of cyclophosphamide, doxorubicin and etoposide (CDE), resulted in 23 complete (CR) and 14 partial responses (PR). Median response duration was 34 weeks. At relapse all patients were retreated with CDE. In 23 (62%) patients this gave a second response (6 CR, 17 PR). Factors influencing the occurrence of a second response were: 1. a CR after the first five cycles of CDE; 18 out of 23 CR patients responded again whereas only five of the 14 PR patients responded (P less than 0.01). 2. 15 out of 19 patients with a first response duration greater than 34 weeks reached a second response and in eight of the other 18 patients retreatment was successful (P less than 0.05). Reinduction at relapse, after short term chemotherapy and a treatment-free interval, with the induction regimen is an effective second line treatment in patients with an initial CR and a first response duration of greater than 34 weeks.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2824211     DOI: 10.1016/0277-5379(87)90128-3

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  41 in total

1.  Treatment of relapse of small cell lung cancer in selected patients with the initial combination chemotherapy carboplatin, etoposide, and epirubicin.

Authors:  P Collard; P Weynants; C Francis; D O Rodenstein
Journal:  Thorax       Date:  1992-05       Impact factor: 9.139

Review 2.  SEOM clinical guidelines for the treatment of small-cell lung cancer 2013.

Authors:  M Dómine Gómez; T Morán Bueno; A Artal Cortés; J Remon Masip; P Lianes Barragán
Journal:  Clin Transl Oncol       Date:  2013-09-05       Impact factor: 3.405

Review 3.  Chemotherapy advances in small-cell lung cancer.

Authors:  Bryan A Chan; Jermaine I G Coward
Journal:  J Thorac Dis       Date:  2013-10       Impact factor: 2.895

Review 4.  Small cell lung cancer: therapies and targets.

Authors:  Rathi N Pillai; Taofeek K Owonikoko
Journal:  Semin Oncol       Date:  2013-12-12       Impact factor: 4.929

5.  A phase II study of carboplatin and vincristine in previously treated patients with small-cell lung cancer.

Authors:  E F Smit; H H Berendsen; E G de Vries; N H Mulder; P E Postmus
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

6.  Chemotherapy in recurrent advanced non-small-cell lung cancer after adjuvant chemotherapy.

Authors:  M Valdes; G Nicholas; G D Goss; P Wheatley-Price
Journal:  Curr Oncol       Date:  2016-12-21       Impact factor: 3.677

Review 7.  Relapsed small cell lung cancer: treatment options and latest developments.

Authors:  Nobuhiro Asai; Yoshihiro Ohkuni; Norihiro Kaneko; Etsuro Yamaguchi; Akihito Kubo
Journal:  Ther Adv Med Oncol       Date:  2014-03       Impact factor: 8.168

8.  A feasibility study of testing new drugs for small-cell lung cancer in patients with a poor performance status.

Authors:  P E Postmus; E F Smit; H H Berendsen; D T Sleyfer
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 9.  Treatment for small cell lung cancer, where are we now?-a review.

Authors:  Gabriela Alvarado-Luna; Daniela Morales-Espinosa
Journal:  Transl Lung Cancer Res       Date:  2016-02

10.  Topotecan in the treatment of relapsed small cell lung cancer.

Authors:  Elisabeth Quoix
Journal:  Onco Targets Ther       Date:  2008-12-01       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.